Company

Our team possesses deep, cross-functional experience and shares a longstanding commitment to developing new medicines to benefit cancer patients.

Management


m-rothera-viracta

Mark Rothera

President and Chief Executive Officer

Darrel-P.-Cohen

Darrel P. Cohen, M.D., Ph.D.

Chief Medical Officer

Mike-Faerm

Michael Faerm, MBA

Chief Financial Officer

Cheryl-Madsen

Cheryl Madsen

Senior Vice President, Regulatory

Biljana

Biljana Nadjsombati, Pharm.D.

Senior Vice President, Pharmaceutical Development

Ruby-Cheema

Ruby Cheema

Vice President, Portfolio and Program Management

Strategic Advisor


Mark A. McCamish, M.D., Ph.D.

Strategic Advisor

Board of Directors


Roger J. Pomerantz, M.D.

Chairman of the Board

Flavia Borellini, Ph.D.

Director

Thomas E. Darcy, CPA

Director

Mark Rothera

President, Chief Executive Officer and Director

Ivor Royston, M.D.

Director

Barry J. Simon, M.D.

Director

Scientific Advisory Board


Douglas V. Faller, M.D., Ph.D.

Scientific Founder and Chairman, Scientific Advisory Board

Robert Baiocchi, M.D., Ph.D.

Scientific Advisor

Gavin Giovannoni, MBBCh, Ph.D., FCP (Neurol., SA), FRCP, FRCPath

Scientific Advisor

Carl June, M.D.

Scientific Advisor

Shannon Kenney, M.D.

Scientific Advisor

Ronald Levy, M.D.

Scientific Advisor

Pierluigi Porcu, M.D.

Scientific Advisor

Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR

Scientific Advisor

Lawrence Young, Ph.D.

Scientific Advisor